Literature DB >> 1094875

D-penicillamine induced Goodpasture's syndrome in Wilson's disease.

I Sternlieb, B Bennett, I H Scheinberg.   

Abstract

Fatal pulmonary hemorrhages and rapidly progressive glomerulonephritis occurred in three patients with Wilson's disease (hepatolenticular degeneration) who had been treated with penicillamine for 2 to 31/2 years. Light microscopic studies of the kidneys showed severe glomerulonephritis with crescent formation, and the lungs showed intraalveolar hemorrhages. Although the clinical and pathologic abnormalities were those of Goodpasture's syndrome, immunofluorescence microscopic studies in the one case tested showed an interrupted, rather than linear, fluorescence pattern.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1094875     DOI: 10.7326/0003-4819-82-5-673

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  29 in total

Review 1.  Penicillamine types in the sclerodermas.

Authors:  T H Tio
Journal:  Proc R Soc Med       Date:  1977

2.  Editorial: Penicillamine: more lessons from experience.

Authors: 
Journal:  Br Med J       Date:  1975-07-19

3.  Diffuse alveolitis as complication of penicillamine treatment for rheumatoid arthritis.

Authors:  C J Eastmond
Journal:  Br Med J       Date:  1976-06-19

Review 4.  Drug-induced pulmonary vascular disease--mechanisms and clinical patterns.

Authors:  K Kumar; W E Holden
Journal:  West J Med       Date:  1986-09

Review 5.  Red cell aplasia following prolonged D-penicillamine therapy.

Authors:  J L Gollan; S Hussein; A V Hoffbrand; S Sherlock
Journal:  J Clin Pathol       Date:  1976-02       Impact factor: 3.411

6.  Glomerulonephritis with coexistent immune deposits and antibasement membrane activity.

Authors:  S Rajaraman; J A Pinto; T Cavallo
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

7.  Relationship of gold and penicillamine therapy to diffuse interstitial lung disease.

Authors:  D L Scott; G V Bradby; T J Aitman; G C Zaphiropoulos; C F Hawkins
Journal:  Ann Rheum Dis       Date:  1981-04       Impact factor: 19.103

8.  Nephrotic syndrome induced by D-penicillamine therapy.

Authors:  P Jezersek; D Ferluga
Journal:  Int Urol Nephrol       Date:  1979       Impact factor: 2.370

9.  Cholestatic jaundice caused by D-penicillamine.

Authors:  D Barzilai; G Dickstein; R Enat; H Bassan; C Lichtig; B Gellei
Journal:  Ann Rheum Dis       Date:  1978-02       Impact factor: 19.103

10.  D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence?

Authors:  A P Andonopoulos; E Terzis; E Tsibri; C A Papasteriades; T Papapetropoulos
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.